Follicum has identified a new class of peptides that increase the insulin secretion in serveral experimental models. Based on this, the company filed a patent application in 2017 to protect Follicum’s peptides. The application is now in PCT phase and has received positive international search report from the European Patent Office (EPO) and was recently published (WO 2018/202870). In preclinical studies performed in later part of 2018, new valuable information has emerged, which is now protected in a new patent application.
|Peptides for treatment of diabetes||2017-2038
Prolongation of the patent term may be possible (for example SPC, PTE) with up to five years in several jurisdictions.
|Awaiting approval: AU, BR, CA, CN, EA, EP, HK, IL, IN, JP, KR, MX, NZ, SG, US and ZA|
|Peptide fragments for treatment of diabetes||2018-2039
Prolongation of the patent term may be possible (for example SPC, PTE) in several jurisdictions.
|PCT application potentially covering 153 jurisdictions|
One of our objectives is to strengthen the patent applications through further preclinical trials and through promising research collaborations. Later on, we intend to identify and select partners to further develop and commercialise the drug.